Aardvark Therapeutics, Inc.AARDEarnings & Financial Report
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-17.7M
Net Profit
$-16.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.75
Aardvark Therapeutics, Inc. Q3 FY2025 Financial Summary
Aardvark Therapeutics, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-16.3M (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-16.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Aardvark Therapeutics, Inc. Annual Revenue by Year
Aardvark Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
Aardvark Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aardvark Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-17.6M | N/A |
| Q3 FY2025 | $0 | — | $-16.3M | N/A |
| Q2 FY2025 | $0 | — | $-14.4M | N/A |
| Q1 FY2025 | $0 | — | $-9.3M | N/A |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $157.0M | $147.5M | $133.2M | $117.2M |
| Liabilities | $6.3M | $10.6M | $10.9M | $10.5M |
| Equity | $150.7M | $136.9M | $122.4M | $106.6M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-11.4M | $-9.8M | $-16.1M | $-16.8M |